Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2024 | Navigating intra-individual variability for early detection of cognitive decline

Leigh Charvet, PhD, New York University Grossman School of Medicine, New York, NY, discusses the use of intra-individual variability (IIV) as a tool to detect cognitive decline in patients with MS and other neurodegenerative diseases. Traditional methods, such as the symbol digit modalities test (SDMT), focus on detecting cognitive impairment after its occurrence, however Prof. Charvet emphasizes the importance of predictive measures to identify those at risk of cognitive decline before it manifests. IIV, reflecting short term within-person changes in performance of psychomotor tasks, has been demonstrated to mark the earliest cognitive changes associated with neurological disease. Prof. Charvet sheds light on her recent study which used the commercial testing platform Cogstate to provide standardized measures of IIV in patients with MS, and highlights how IIV could be a game-changer in personalized care for individuals with early MS. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.